Investor Relations

Polaris Group (the “Company” or “Polaris”) was incorporated in the British Cayman Islands on February 9, 2006 with a par value of NT$10 per share. The Company and its subsidiaries include Polaris Pharmaceuticals, Inc. Polaris Pharmaceuticals Ireland Limited, Ruihua Pharmaceuticals Research & Development Company Limited, DesigneRx Pharmaceuticals, Inc. Ltd. The Group’s principal business activities are the manufacture and sale of new drugs, biotechnology services and drug testing. The Group’s core research is the novel cancer target drug ADI-PEG 20, which is currently undergoing human clinical trials for various cancers worldwide.


Scroll to Top